

## Phenylalanin

### In Short

- **Phenylalanin** is a Food for Special Medical Purposes (FSMP) for use in the dietary management of rare metabolic disorders, e.g. Tyrosinemia, Alkaptonuria or FARS2 Deficiency, when supplementation with L-Phenylalanine is indicated
- suitable from birth onwards
- L-Phenylalanine – in powder form
- suitable for tube feeding
- 150 g tin

Journal of Inherited Metabolic Disease 23(7):677-83. doi: 10.1023/a:1005666426079.

### Product Profile

**Phenylalanin** is highly concentrated L-Phenylalanine in powder form.

**Phenylalanin** is not fortified with micro-nutrients.

Suitable from birth onwards.

### Administration

**Phenylalanin** should be taken along with other food and supplementary to the regular protein supplement – if applicable.

**Phenylalanin** is also suitable for tube feeding.

### Preparation

**Phenylalanin** may be mixed with the protein supplement as needed and taken with it. Stirred into liquids, such as water, (diluted) juice or milk (substitute), it should be drunk quickly. **Phenylalanin** may also be prepared with fruit puree and other foods permitted within the scope of the respective dietary management.

Always weigh the amount of **Phenylalanin** needed. Always prepare freshly.

□ □ □  
**Function** **Phenylalanin** is suitable for prevention or correction of disease related L-Phenylalanine deficiencies.

**Dosage** The daily dosage depends on age, body weight and individual medical condition, and is, just as the right time for the daily intake, determined under medical supervision.

**Phenylalanin** can easily be combined with the products of the ZeroTP-system.

**Important Notice** Must only be used under medical supervision. Not for use as a sole source of nutrition. For enteral use

only. Only for people with rare metabolic disorders, e.g. Tyrosinemia, Alkaptonuria or FARS2 Deficiency. **Phenylalanin** is suitable from birth onwards.

#### References:

- Daly et al. (2012) Diurnal variation of phenylalanine concentrations in tyrosinaemia type 1: should we be concerned?; Journal of Human Nutrition and Dietetics 25(2):111-6. doi: 10.1111/j.1365-277X.2011.01215.x. Epub 2011 Dec 15.
- de Laet et al. (2011) Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type I; Developmental Medicine & Child Neurology 53(10):962-4. doi: 10.1111/j.1469-8749.2011.04048.x. Epub 2011 Jul 11.
- de Laet et al. (2013) Recommendations for the management of tyrosinaemia type 1; Orphanet Journal of Rare Diseases (8):8. doi: 10.1186/1750-1172-8-8.
- Kok et al. (2021) Treatment of ARS deficiencies with specific amino acids; Genetics in Medicine 23(11):2202-2207. doi: 10.1038/s41436-021-01249-z. Epub 2021 Jun 30.
- Konolova et al. (2013) Mitochondrial aminoacyl-tRNA synthetases in human disease; Molecular Genetics and Metabolism 108(4):206-11. doi: 10.1016/j.ymgme.2013.01.010. Epub 2013 Jan 26.
- Oswald et al. (2023) Treatment of Mitochondrial Phenylalanyl-tRNA-Synthetase Deficiency (FARS2) with Oral Phenylalanine; Neuropediatrics 54(5):351-355. doi: 10.1055/a-2008-4230. Epub 2023 Jan 5.
- van et al. (2014) Single amino acid supplementation in aminoacidopathies: a systematic review. Orphanet journal of rare diseases 9:7. doi: 10.1186/1750-1172-9-7.
- van Vliet et al. (2015) Infants with Tyrosinemia Type 1: Should phenylalanine be supplemented? Journal of Inherited Metabolic Disease reports 2015:18:117-24. doi: 10.1007/8904\_2014\_358. Epub 2014 Sep 26.
- Wilson et al. (2000) Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia;

## NUTRITION INFORMATION

Phenylalanin

100 g

<b>Energy</b>	<b>kJ</b>	<b>1417</b>
	<b>kcal</b>	<b>333</b>
<b>Fat</b>	<b>g</b>	<b>0</b>
of which saturates	g	0
<b>Carbohydrate</b>	<b>g</b>	<b>0</b>
of which sugars	g	0
<b>Protein eqv.</b>	<b>g</b>	<b>83</b>
of which L-Phenylalanine	g	100
<b>Salt</b>	<b>g</b>	<b>0</b>

## INGREDIENTS

L-phenylalanine.

Delivery Unit	tin 150 g
Article Number	xx-001-98022
Delivery to	Pharmacies, clinics
Storage	Store in a cool, dry place.